Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)

被引：146

作者：

Baumann, M. ^{[1
,2
]}

Herrmann, T. ^{[2
]}

Koch, R. ^{[3
]}

Matthiessen, W. ^{[4
]}

Appold, S. ^{[2
]}

Wahlers, B. ^{[5
]}

Kepka, L. ^{[6
]}

Marschke, G. ^{[7
]}

Feltl, D. ^{[8
]}

Fietkau, R. ^{[9
]}

Budach, V. ^{[10
]}

Dunst, J. ^{[11
]}

Dziadziuszko, R. ^{[12
]}

Krause, M. ^{[2
]}

Zips, D. ^{[2
]}

机构：

[1] Tech Univ Dresden, Dept Radiat Oncol, Univ Hosp CG Carus, D-01307 Dresden, Germany

[2] Tech Univ Dresden, Dept Radiat Oncol, D-01307 Dresden, Germany

[3] Tech Univ Dresden, Inst Informat & Biometry, Fac Med, D-01307 Dresden, Germany

[4] Lungenfachklin Coswig, Dept Pneumol, Coswig, Germany

[5] Lungenklin Hemer, Dept Radiotherapy, Hemer, Germany

[6] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Radiat Therapy, Warsaw, Poland

[7] Stadt Klinikum Gorlitz GmbH, Dept Radiat Therapy, Gorlitz, Germany

[8] Univ Hosp Kralovkse Vinohrady, Dept Radiotherapy & Oncol, Prague, Czech Republic

[9] Univ Rostock, Dept Radiotherapy, D-2500 Rostock 1, Germany

[10] Univ Hosp Charite, Dept Radiotherapy, Berlin, Germany

[11] Univ Halle Wittenberg, Dept Radiotherapy, Halle, Germany

[12] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

来源：

RADIOTHERAPY AND ONCOLOGY | 2011年 / 100卷 / 01期

关键词：

Non-small cell lung cancer; Accelerated radiotherapy; Randomized trial; Time factor; TREATMENT TIME; MULTICENTER TRIAL; NEOADJUVANT CHEMOTHERAPY; CLONOGEN REPOPULATION; DOSE-ESCALATION; LIMITED-STAGE; WEEKEND LESS; NUDE-MICE; COMPENSATION; METAANALYSIS;

D O I：

10.1016/j.radonc.2011.06.031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Continuous hyperfractionated accelerated radiotherapy (CHART) counteracts repopulation and may significantly improve outcome of patients with non-small-cell lung cancer (NSCLC). Nevertheless high local failure rates call for radiation dose escalation. We report here the final results of the multicentric CHARTWEL trial (CHART weekend less, ARO 97-1). Patients and methods: Four hundred and six patients with NSCLC were stratified according to stage, histology, neoadjuvant chemotherapy and centre and were randomized to receive 3D-planned radiotherapy to 60 Gy/40 fractions/2.5 weeks (CHARTWEL) or 66 Gy/33 fractions/6.5 weeks (conventional fractionation, CF). Results: Overall survival (OS, primary endpoint) at 2, 3 and 5 yr was not significantly different after CHARTWEL (31%, 22% and 11%) versus CF (32%, 18% and 7%; HR 0.92, 95% Cl 0.75-1.13, p = 0.43). Also local tumour control rates and distant metastases did not significantly differ. Acute dysphagia and radiological pneumonitis were more pronounced after CHARTWEL, without differences in clinical signs of pneumopathy. Exploratory analysis revealed a significant trend for improved LC after CHARTWEL versus CF with increasing UICC, T or N stage (p = 0.006-0.025) and after neoadjuvant chemotherapy (HR 0.48, 0.26-0.89, p = 0.019). Conclusions: Overall, outcome after CHARTWEL or CF was not different. The lower total dose in the CHARTWEL arm was compensated by the shorter overall treatment time, confirming a time factor for NSCLC. The higher efficacy of CHARTWEL versus CF in advanced stages and after chemotherapy provides a basis for further trials on treatment intensification for locally advanced NSCLC. (c) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 100 (2011) 76-85

引用

页码：76 / 85

页数：10

共 43 条

[31]

LANG K, 2010, MED FAKULTAT CG CARU

[32]

Lehmann D, 2003, STRAHLENTHER ONKOL, V179, P152, DOI 10.1007/s00066-003-1008-1

[33]

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006-2007 [J].